DelveInsight’s, “Brain Metastases Pipeline Insights 2026” report provides comprehensive insights about 40+ Brain Metastases companies and 45+ pipeline drugs in Brain Metastases pipeline landscape. It covers the Brain Metastases pipeline drug profiles, including clinical and nonclinical stage products. Brain Metastases pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Brain Metastases Pipeline Outlook Report
Key Takeaways from the Brain Metastases Pipeline Report
- On March 10, 2026- MedSIR initiated a phase II study aiming to gather additional solid evidence of Trastuzumab-Deruxtecan (T-DXd) activity in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-low breast cancer with active brain metastases. This study will analyze the efficacy of T-DXd as determined by overall response rate (ORR) at any timepoint as judged by best CNS response according to RANO-BM criteria.
- On March 02, 2026- M.D. Anderson Cancer Center conducted a phase II study to assess the safety and efficacy of the combination of nivolumab with ipilimumab and cabozantinib in patients with untreated brain metastases from RCC until disease progression or intolerable toxicities or patient withdrawal. We will accrue a total of 40 patients. Patients will be treated with nivolumab (3mg/kg) and ipilimumab (1mg/kg) IV every 3 weeks for 4 doses and cabozantinib 40mg daily. Then patients will be treated with nivolumab 480mg IV Q 4 weeks and cabozantinib 40mg daily until progression or intolerable toxicities or patient’s withdrawal. A lead-in group of 6 patients will be closely monitored for DLT.
- DelveInsight’s Brain Metastases pipeline report depicts a robust space with 40+ active players working to develop 45+ pipeline therapies for Brain Metastases treatment.
- The leading Brain Metastases Companies such as HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
- Promising Brain Metastases Pipeline Therapies such as GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib and others.
Learn how leading Brain Metastases Companies are positioning themselves for success in the evolving pharmaceutical market @ Brain Metastases Clinical Trials Assessment
The Brain Metastases Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Brain Metastases Pipeline Report also highlights the unmet needs with respect to the development of Brain Metastases.
Brain Metastases Overview
Brain metastases are a common complication of cancer and the most common type of brain tumor. Anywhere from 10% to 26% of patients who die from their cancer will develop brain metastases. While few cancers that metastasize to the brain can be cured using conventional therapies, long-term survival and palliation are possible with minimal adverse effects to patients. Increasingly, neuro-cognition and quality of life are being recognized as important endpoints for patients as survival continues to increase.
Brain Metastases Emerging Drugs Profile
- ANG1005: Angiochem
ANG1005 is a novel targeted taxane derivative that is the first oncology product to leverage Angiochem’s technology platform to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 is an Angiopep-2 paclitaxel conjugate that gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the BBB. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.
- Azeliragon: Cantex Pharmaceuticals, Inc.
Azeliragon, is an oral, small molecule, administered once-daily, that inhibits RAGE interactions with its natural ligands, including HMGB1 and S100 proteins, in the tumor microenvironment. Activation of RAGE by these ligands stimulates cancer and its progression and metastasis and resistance to cancer treatment.
- AZD3759: Alpha Biopharma Ltd.
Zorifertinib (AZD3759) is a type of reversible new generation EGFR TKI, which has a strong ability to penetrate the bloodstream, cerebrospinal fluid, and can reach blood volume in the tissue. It is currently investigated for brain metastases and completed Phase II/III trial in July 2022.
From early-stage research to late-phase Brain Metastases Clinical Trials, our analysis covers companies @ Brain Metastases Treatment Drugs
The Brain Metastases Pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Brain Metastases with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Brain Metastases Treatment.
- Brain Metastases Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Brain Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Brain Metastases market.
Brain Metastases Companies
HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
Brain metastases pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Brain Metastases Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Download our report for a deep dive into the next generation of therapeutics! @ Brain Metastases Market Drivers and Barriers, and Future Perspectives
Scope of the Brain Metastases Pipeline Report
- Coverage- Global
- Brain Metastases Companies- HUYA Bioscience International, LLC, Angiochem, Cantex Pharmaceuticals, Inc., Bristol-Myers Squibb, ImmunoChem Therapeutics, LLC, Kazia Therapeutics, Alpha Biopharma Ltd, Betta Pharmaceuticals Co., Ltd., TYK Medicines, Inc., BioMimetix JV, LLC, Amgen, Jubilant Therapeutics, Quadriga Biosciences, Inc., Pfizer, Medolution Ltd., Puma Biotechnology, Inc., Seagen Inc., Jiangsu Hansoh Pharmaceutical Co., Ltd., ABM Therapeutics Corporation and others.
- Brain Metastases Pipeline Therapies- GLIADEL, 18F fluciclovine, Pembrolizumab, IPILIMUMAB, Cabozantinib, Trastuzumab, capecitabine, lapatinib, Lenvatinib and others.
- Brain Metastases Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Brain Metastases Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find answers in our latest Brain Metastases Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs @ Brain Metastases Emerging Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Brain metastases: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Brain metastases– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- ANG1005: Angiochem
- Mid Stage Products (Phase II)
- Paxalisib: Kazia Therapeutics
- Early Stage Products (Phase I)
- MW151: ImmunoChem Therapeutics, LLC
- Preclinical and Discovery Stage Products
- JBI-2174: Jubilant Therapeutics
- Inactive Products
- Brain metastases Key Companies
- Brain metastases Key Products
- Brain metastases- Unmet Needs
- Brain metastases- Market Drivers and Barriers
- Brain metastases- Future Perspectives and Conclusion
- Brain metastases Analyst Views
- Brain metastases Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/brain-metastases-pipeline-insight